A Phase 1 interventional study of Olpasiran in Elevated Serum Lipoprotein(a), sponsored by Amgen. Completed at 1 site in Hong Kong. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by Amgen · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of Olpasiran in Chinese participants with elevated serum lipoprotein(a) (Lp[a]).
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion eligibility criteria will be evaluated in 2 parts during the screening period:
Part 1:
Part 2:
Females must be of non-:
a. defined as: i. Age of ≥ 55 years with no menses for at least 12 months; OR ii. Age of \< 55 years with no menses for at least 12 months AND with a follicle stimulating hormone (FSH) level > 40 IU/L or according to the definition of "postmenopausal range" for the laboratory involved; OR b. History of hysterectomy; OR c. History of bilateral oophorectomy.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered Olpasiran dose A as a subcutaneous injection.
Drug: Olpasiran
Participants will be administered Olpasiran dose B as a subcutaneous injection.
Drug: Olpasiran
Subcutaneous injection
Also known as: AMG 890
Maximum Observed Concentration (Cmax) of Olpasiran
The serum pharmacokinetic (PK) parameters of olpasiran were calculated using standard noncompartmental methods.
Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Area Under the Serum Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Olpasiran
The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.
Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Olpasiran
The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.
Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Time to Cmax (Tmax) of Olpasiran
The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.
Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Apparent Terminal Elimination Half-life (T1/2) of Olpasiran
The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.
Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Olpasiran
The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.
Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Apparent Total Body Clearance (CL/F) of Olpasiran
The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.
Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was defined as an AE that starts on or after the first dose of investigational product and up to end of study. Clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms, and vital signs were reported as AEs.
Time frame: Up to Day 225
Percentage Change From Baseline in Triglycerides
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
Time frame: Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C)
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
Time frame: Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
Time frame: Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
Time frame: Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in Total Cholesterol
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
Time frame: Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in Apolipoprotein A1 (ApoA1)
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
Time frame: Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in Apolipoprotein B (Apo B)
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
Time frame: Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in Lipoprotein-a (Lp[a])
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
Time frame: Baseline and Days 2, 4, 7, 15, 29, 57, 85, 113, 155, 183 and 225
| Milestone | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 11 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
The serum pharmacokinetic (PK) parameters of olpasiran were calculated using standard noncompartmental methods.
| ng/mL | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Maximum Observed Concentration (Cmax) of Olpasiran | 144 ± 55.5 | 549 ± 71.5 |
The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.
| h*ng/mL | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Area Under the Serum Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Olpasiran | 2660 ± 24.0 | 12000 ± 41.2 |
The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.
| h*ng/mL | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Olpasiran | 2660 ± 24.2 | 12000 ± 41.3 |
The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.
| hours | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Time to Cmax (Tmax) of Olpasiran | 3.02 (2.85 to 9.00) | 3.11 (2.88 to 12.0) |
The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.
| hours | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Apparent Terminal Elimination Half-life (T1/2) of Olpasiran | 6.05 ± 1.59 | 6.69 ± 1.58 |
The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.
| liters | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Olpasiran | 238 ± 43.5 | 176 ± 60.2 |
The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.
| L/h | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Apparent Total Body Clearance (CL/F) of Olpasiran | 28.2 ± 24.0 | 18.8 ± 41.2 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was defined as an AE that starts on or after the first dose of investigational product and up to end of study. Clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms, and vital signs were reported as AEs.
| Participants | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) | 12 | 10 |
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
| percentage change in triglycerides | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Day 7 | 21.8 ± 30.1 | -10.0 ± 39.1 |
| Day 15 | 10.4 ± 33.2 | -12.9 ± 22.1 |
| Day 57 | 7.55 ± 35.1 | -2.35 ± 36.3 |
| Day 155 | -2.87 ± 32.8 | -16.2 ± 25.3 |
| Follow-up (Day 225) | 26.6 ± 50.7 | -10.4 ± 23.7 |
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
| percentage change in VLDL-C | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Day 7 | 23.5 ± 37.7 | -8.43 ± 40.2 |
| Day 15 | 13.5 ± 41.8 | -8.10 ± 32.3 |
| Day 57 | 7.94 ± 38.3 | 4.55 ± 60.4 |
| Day 155 | -0.165 ± 43.1 | -11.9 ± 39.0 |
| Follow-up (Day 225) | 26.7 ± 48.4 | -7.58 ± 28.1 |
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
| percentage change in LDL-C | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Day 7 | -4.17 ± 13.1 | 1.22 ± 8.36 |
| Day 15 | -0.843 ± 14.3 | 3.97 ± 11.9 |
| Day 57 | 0.201 ± 9.64 | 2.29 ± 9.73 |
| Day 155 | -5.91 ± 13.5 | -3.82 ± 12.6 |
| Follow-up (Day 225) | 2.01 ± 17.7 | -5.55 ± 10.9 |
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
| percentage change in HDL-C | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Day 7 | 3.80 ± 7.28 | 7.41 ± 6.57 |
| Day 15 | 6.65 ± 6.18 | 11.0 ± 5.97 |
| Day 57 | 7.17 ± 10.8 | 1.29 ± 8.40 |
| Day 155 | 21.8 ± 11.0 | 21.3 ± 9.82 |
| Follow-up (Day 225) | 13.9 ± 5.25 | 11.3 ± 15.3 |
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
| percentage change in total cholesterol | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Day 7 | 0.923 ± 10.2 | 0.956 ± 6.78 |
| Day 15 | 2.45 ± 9.52 | 3.70 ± 9.03 |
| Day 57 | 2.17 ± 7.41 | 0.879 ± 7.20 |
| Day 155 | 1.20 ± 9.71 | 0.689 ± 8.03 |
| Follow-up (Day 225) | 6.95 ± 9.43 | -1.82 ± 8.33 |
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
| percentage change in ApoA1 | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Day 7 | 2.86 ± 9.63 | 3.75 ± 9.46 |
| Day 15 | 8.10 ± 5.61 | 7.95 ± 8.65 |
| Day 57 | 0.185 ± 8.20 | -0.294 ± 8.32 |
| Day 155 | 11.4 ± 9.46 | 9.31 ± 9.47 |
| Follow-up (Day 225) | 18.1 ± 8.27 | 11.7 ± 14.0 |
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
| percentage change in Apo B | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Day 7 | 0.0576 ± 11.1 | 1.41 ± 7.54 |
| Day 15 | 2.65 ± 8.99 | 1.77 ± 9.34 |
| Day 57 | 3.66 ± 10.0 | 1.59 ± 8.49 |
| Day 155 | -0.834 ± 12.9 | -0.958 ± 9.01 |
| Follow-up (Day 225) | 5.64 ± 12.4 | -1.90 ± 11.5 |
Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.
| percentage change in Lp(a) | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Day 2 | 0.245 ± 8.57 | -0.295 ± 9.84 |
| Day 4 | -4.93 ± 11.4 | -17.6 ± 12.6 |
| Day 7 | -32.9 ± 13.2 | -49.8 ± 16.3 |
| Day 15 | -77.3 ± 8.46 | -84.2 ± 10.7 |
| Day 29 | -91.0 ± 4.20 | -95.2 ± 5.50 |
| Day 57 | -94.8 ± 3.80 | -99.2 ± 1.65 |
| Day 85 | -91.4 ± 9.89 | -98.9 ± 1.84 |
| Day 113 | -87.8 ± 11.1 | -97.7 ± 2.84 |
| Day 155 | -75.8 ± 17.9 | -93.7 ± 5.13 |
| Day 183 | -67.3 ± 18.0 | -89.1 ± 8.17 |
| Follow-up (Day 225) | -55.1 ± 18.5 | -81.5 ± 11.8 |
Collected over Up to 225 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olpasiran Low Dose | 0/12 (0%) | 1/12 (8.3%) | 11/12 (91.7%) |
| Olpasiran High Dose | 0/12 (0%) | 1/12 (8.3%) | 9/12 (75%) |
| Event | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| Clavicle fractureInjury, poisoning and procedural complications | 1/12 | 0/12 |
| Alanine aminotransferase increasedInvestigations | 0/12 | 1/12 |
| Aspartate aminotransferase increasedInvestigations | 0/12 | 1/12 |
| Event | Olpasiran Low Dose | Olpasiran High Dose |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/12 | 1/12 |
| PyrexiaGeneral disorders | 3/12 | 0/12 |
| Covid-19Infections and infestations | 1/12 | 3/12 |
| Injection site erythemaGeneral disorders | 0/12 | 2/12 |
| ContusionInjury, poisoning and procedural complications | 1/12 | 2/12 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/12 | 0/12 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/12 | 0/12 |
| RashSkin and subcutaneous tissue disorders | 2/12 | 1/12 |
| Abdominal discomfortGastrointestinal disorders | 0/12 | 1/12 |
| GastritisGastrointestinal disorders | 1/12 | 0/12 |
Safety Analysis Set: included all randomized participants who received olpasiran.
| Age, Continuous(years) | Olpasiran Low Dose | Olpasiran High Dose | Total |
|---|---|---|---|
| Mean | 41.3 ± 11.23 | 49.4 ± 9.23 | 45.3 ± 10.88 |
| Sex: Female, Male(Participants) | Olpasiran Low Dose | Olpasiran High Dose | Total |
|---|---|---|---|
| Female | 2 | 5 | 7 |
| Male | 10 | 7 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Olpasiran Low Dose | Olpasiran High Dose | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 12 | 12 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Olpasiran Low Dose | Olpasiran High Dose | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 12 | 12 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Jul 2021 to primary completion in Nov 2021, 3 months.
Results were first posted in Feb 2025, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olpasiran